Diego Ruiz Espi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Diego Ruiz Espi has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Timothy Patrick Jenkins
Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark
3 shared publications - Max D. Overath
Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark
2 shared publications - Andreas Hald
Global Research Technologies
1 shared publication - Andreas Hougaard Laustsen
Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark
1 shared publication - Aske Unger
Center for Translational Protein Design, Technical University of Denmark, Søltofts Plads, Building 221, Kongens Lyngby, 2800, Denmark
1 shared publication Carol O'BRien
Tech Univ Denmark, Dept Biotechnol & Biomed, Lyngby, Denmark
1 shared publication
Latest Publications
- Open Access
A rapid, automation-friendly, cell-free and purification-free pipeline for binding and kinetic characterisation of de novo designed binders with high quality standardised per-design data
De novo protein binders can now be generated far faster than they can be tested. Current validation routes — display selection, cell-free two-hybrid assays, or surface-based biophysics — require cell culture, colony picking, protein purification, target labeling or sensor immobilisation, take 2 to 8 weeks, and require additional methods for affinity and kinetics characterisation. Here we report an end-to-end, cell- and purification-free pipeline that goes from gene to binding affinity and kinetics in three days without genetically modified organisms, cell culture, purification, labelling or immobilisation. An automated, metric-driven loop of RFdiffusion, ProteinMPNN and AlphaFold2 initial-guess generates and filters designs, which are ranked by Boltz-2 ipSAE, assembled by Golden Gate cloning from linear DNA, expressed in a cell-free protein synthesis lysate as fluorescent protein fusions, and screened directly in the unpurified product by flow-induced dispersion analysis (FIDA). Against human growth hormone, 11 of 30 designs (37%) bound, and the four strongest had equilibrium dissociation constants of 0.93–9.98 nM with on- and off-rates resolved from the same cell-free material. Each sample run measures expression level, hydrodynamic radius, oligomeric and aggregation state alongside the binding readout, producing the standardised, per-design datasets that model training requires.
Open AccessA rapid, automation-friendly, cell-free and purification-free pipeline for binding and kinetic characterisation of de novo designed binders with high quality standardised per-design data
De novo protein binders can now be generated far faster than they can be tested. Current validation routes — display selection, cell-free two-hybrid assays, or surface-based biophysics — require cell culture, colony picking, protein purification, target labeling or sensor immobilisation, take 2 to 8 weeks, and require additional methods for affinity and kinetics characterisation. Here we report an end-to-end, cell- and purification-free pipeline that goes from gene to binding affinity and kinetics in three days without genetically modified organisms, cell culture, purification, labelling or immobilisation. An automated, metric-driven loop of RFdiffusion, ProteinMPNN and AlphaFold2 initial-guess generates and filters designs, which are ranked by Boltz-2 ipSAE, assembled by Golden Gate cloning from linear DNA, expressed in a cell-free protein synthesis lysate as fluorescent protein fusions, and screened directly in the unpurified product by flow-induced dispersion analysis (FIDA). Against human growth hormone, 11 of 30 designs (37%) bound, and the four strongest had equilibrium dissociation constants of 0.93–9.98 nM with on- and off-rates resolved from the same cell-free material. Each sample run measures expression level, hydrodynamic radius, oligomeric and aggregation state alongside the binding readout, producing the standardised, per-design datasets that model training requires.
- Open Access
De novo designed single-domain antibodies protect against lethal cobra venom neurotoxicity in vivo
Generative protein design can now rapidly produce de novo binders with high affinity and functional activity against a wide range of targets, including lethal snake venom toxins. However, so far most reported successes rely on new-to-nature scaffolds with limited therapeutic precedent. Single-domain antibodies (V H Hs) offer a clinically validated alternative scaffold that can bind and neutralize long-chain α -neurotoxins, which are some of the most lethal components in snake venoms. Here we compare three recently established de novo design models with V H H-design capabilities (Germinal, RFantibody, and BoltzGen) for their ability to generate V H Hs against the neurotoxin α -cobratoxin from the monocled cobra ( Naja kaouthia ). Using standardized model inputs and evaluation criteria based on AlphaFold3 interface confidence (ipTM) and RMSD self-consistency, we find that Germinal was the only method to generate designs passing stringent in silico criteria for experimental testing. We therefore performed a larger Germinal design campaign employing three different V H H frameworks and experimentally validated 46 designs in vitro . Of these, 42 expressed as soluble proteins and we identified four binding hits derived from two of the three tested frameworks. Of the four binders, two lead candidates were further characterized and demonstrated high affinity (K D s of 4.1 nM and 10.8 nM), monomeric behavior and low polyreactivity, indicating favorable biophysical and developability properties, as well as functional toxin neutralization in vitro . To assess their therapeutic potential we investigated their ability to protect against α -cobratoxin toxicity in vivo . Both candidates fully protected mice after α -cobratoxin challenge, with 100% survival compared to a lethal control. One candidate also retained notable neutralization capacity against whole venom of Naja kaouthia with a survival of 56%, while the other protected 22% when tested in a rescue setting. Together, we demonstrate that de novo V H H design can generate high affinity single-domain antibodies with in vivo protection against lethal cobra venom neurotoxicity, and provide practical insights into method- and framework-dependent performance.
Open AccessDe novo designed single-domain antibodies protect against lethal cobra venom neurotoxicity in vivo
Generative protein design can now rapidly produce de novo binders with high affinity and functional activity against a wide range of targets, including lethal snake venom toxins. However, so far most reported successes rely on new-to-nature scaffolds with limited therapeutic precedent. Single-domain antibodies (V H Hs) offer a clinically validated alternative scaffold that can bind and neutralize long-chain α -neurotoxins, which are some of the most lethal components in snake venoms. Here we compare three recently established de novo design models with V H H-design capabilities (Germinal, RFantibody, and BoltzGen) for their ability to generate V H Hs against the neurotoxin α -cobratoxin from the monocled cobra ( Naja kaouthia ). Using standardized model inputs and evaluation criteria based on AlphaFold3 interface confidence (ipTM) and RMSD self-consistency, we find that Germinal was the only method to generate designs passing stringent in silico criteria for experimental testing. We therefore performed a larger Germinal design campaign employing three different V H H frameworks and experimentally validated 46 designs in vitro . Of these, 42 expressed as soluble proteins and we identified four binding hits derived from two of the three tested frameworks. Of the four binders, two lead candidates were further characterized and demonstrated high affinity (K D s of 4.1 nM and 10.8 nM), monomeric behavior and low polyreactivity, indicating favorable biophysical and developability properties, as well as functional toxin neutralization in vitro . To assess their therapeutic potential we investigated their ability to protect against α -cobratoxin toxicity in vivo . Both candidates fully protected mice after α -cobratoxin challenge, with 100% survival compared to a lethal control. One candidate also retained notable neutralization capacity against whole venom of Naja kaouthia with a survival of 56%, while the other protected 22% when tested in a rescue setting. Together, we demonstrate that de novo V H H design can generate high affinity single-domain antibodies with in vivo protection against lethal cobra venom neurotoxicity, and provide practical insights into method- and framework-dependent performance.